11 Dec 2019
Steve Rees, Vice President Discovery Biology at AstraZeneca and Chair of ELRIG, discusses the latest technologies and techniques advancing drug discovery, including CRISPR, cryo-electron microscopy, PROTACS, artificial intelligence and machine learning. Rees describes the approach AstraZeneca have taken to try and make every target druggable and shares some of his highlights from this year’s ELRIG Drug Discovery meeting, held in Liverpool, UK, including activities that engage early careers professionals and award-winning innovative technologies.
AstraZeneca
Steve Rees is Vice-President of Screening Sciences and Sample Management at AstraZeneca with global responsibility for High Throughput Screening and Compound Management. Steve has written more than 60 scientific papers and has spoken at many international symposia including at the Society of Laboratory Automation and Screening (SLAS). He is currently Chair of the SLAS Europe Council .